ライフサイエンスコーパス: metabolic disorder

1 ice an HFD for 16 wk to initiate HFD-induced metabolic disorder.

2 r, cardiovascular disease, autoimmunity, and metabolic disorder.

3 robiotics to attenuate high-fat diet-related metabolic disorder.

4 nd adoptive transfer of AT1-ILCs exacerbated metabolic disorder.

5 dities, including cardiovascular disease and metabolic disorder.

6 as a consideration in the treatment of liver metabolic disorders.

7 , non-alcoholic steatohepatitis, and related metabolic disorders.

8 4 in managing obesity and obesity-associated metabolic disorders.

9 e (NNMT), an enzyme implicated in cancer and metabolic disorders.

10 ts a therapeutic avenue for the treatment of metabolic disorders.

11 mproved therapeutic strategies for combating metabolic disorders.

12 ssociated with increased risk for immune and metabolic disorders.

13 ntergenerational inheritance of diet-induced metabolic disorders.

14 iabetes may lead to promising treatments for metabolic disorders.

15 d has the potential to treat obesity-related metabolic disorders.

16 contribute to muscle wasting associated with metabolic disorders.

17 and excessive storage is a feature of common metabolic disorders.

18 le similar to dysbiotic states described for metabolic disorders.

19 rone is associated with all "Western" cardio-metabolic disorders.

20 c and diagnostic targets for obesity-related metabolic disorders.

21 who may be at higher risk for cardiovascular/metabolic disorders.

22 Indians are known to be at elevated risk for metabolic disorders.

23 cluster of cardiovascular (hypertension) and metabolic disorders.

24 -MCA may be a candidate for the treatment of metabolic disorders.

25 ives to combat the rising global epidemic of metabolic disorders.

26 be associated with chronic liver disease and metabolic disorders.

27 reat neuroinflammation, obesity, and related metabolic disorders.

28 rnutrition increases the risk of obesity and metabolic disorders.

29 ce their pathogenic role in inflammatory and metabolic disorders.

30 on that contributes to bone dysregulation in metabolic disorders.

31 omic loci contributing to cardiovascular and metabolic disorders.

32 nalog, could be developed as a treatment for metabolic disorders.

33 broader significance to other peripheral and metabolic disorders.

34 mation in the pathophysiology of obesity and metabolic disorders.

35 ed to aging, neurodegenerative diseases, and metabolic disorders.

36 rapeutic route to combat obesity and related metabolic disorders.

37 al approach to reversing obesity and related metabolic disorders.

38 and represents a possible new drug target in metabolic disorders.

39 l treatment for human obesity and associated metabolic disorders.

40 e treatment of stress-related psychiatric or metabolic disorders.

41 rnal desynchrony, which promotes obesity and metabolic disorders.

42 receptor (LepR) leads to severe obesity and metabolic disorders.

43 e also resistant to diet-induced obesity and metabolic disorders.

44 vators in the treatment of insulin-resistant metabolic disorders.

45 tors are required for long-term treatment of metabolic disorders.

46 investigate the connection between IL-22 and metabolic disorders.

47 n, and reduce cardiac derangements caused by metabolic disorders.

48 raphical disparities, such as autoimmune and metabolic disorders.

49 d with high-fat diet are prone to developing metabolic disorders.

50 in energy expenditure and in age-associated metabolic disorders.

51 arning and are implicated in glucose-related metabolic disorders.

52 but these pathways are often dysregulated in metabolic disorders.

53 ortant role in determining susceptibility to metabolic disorders.

54 dults opens attractive perspectives to treat metabolic disorders.

55 y contributes to the pathogenesis of diverse metabolic disorders.

56 utive enzymatic treatment of other inherited metabolic disorders.

57 a inhibitors in the treatment of obesity and metabolic disorders.

58 teria induce a metabolic endotoxemia leading metabolic disorders.

59 LT2B1b as a potential therapeutic target for metabolic disorders.

60 olong sitting has been found associated with metabolic disorders.

61 egy for combating obesity and its associated metabolic disorders.

62 romising drug candidate for the treatment of metabolic disorders.

63 hat has recently been implicated in mood and metabolic disorders.

64 ctive strategy to inhibit the development of metabolic disorders.

65 cidate the effect of KHK inhibition on these metabolic disorders.

66 ces dysbiosis, which is associated with host metabolic disorders.

67 present a potential drug target for treating metabolic disorders.

68 eratrol as a human nutritional supplement in metabolic disorders.

69 ch ratios as a new clinical biomarker for Fe metabolic disorders.

70 besity is a primary risk factor for multiple metabolic disorders.

71 ls as potential risk factors for obesity and metabolic disorders.

72 of photosensitivity to inherited genetic or metabolic disorders.

73 nt and nonmalignant hematologic diseases and metabolic disorders.

74 cRNA roles in complex neurodevelopmental and metabolic disorders.

75 ant for the treatment of obesity and related metabolic disorders.

76 , is a sensitive clinical biomarker for iron metabolic disorders.

77 etabolism that mitigates the consequences of metabolic disorders.

78 and potentially new targets in treatment of metabolic disorders.

79 molecule activators of AMPK for treatment of metabolic disorders.

80 ly possible applications in the treatment of metabolic disorders.

81 es a promising approach for the treatment of metabolic disorders.

82 a risk factor for various cardiovascular and metabolic disorders.

83 ential cofactor in inflammatory diseases and metabolic disorders.

84 as the premature aging disease progeria and metabolic disorders.

85 oordinated treatment of functionally related metabolic disorders.

86 n or treatment of obesity and its associated metabolic disorders.

87 ic target for the intervention of cancer and metabolic disorders.

88 und benefits in the treatment of obesity and metabolic disorders.

89 utic strategy to protect against obesity and metabolic disorders.

90 that central vascular impairments may cause metabolic disorders.

91 sing CRISPR/Cas9, as a new strategy to model metabolic disorders.

92 ating obesity, diabetes and their associated metabolic disorders.

93 e promising agents for treating a variety of metabolic disorders.

94 cally relevant for the prevention of glucose metabolic disorders.

95 munity to pathogens/tumors and in autoimmune/metabolic disorders.

96 safety profiles in the treatment of complex metabolic disorders.

97 ptation to ER stress associated with chronic metabolic disorders.

98 in the aetiology of sleep, mental health and metabolic disorders.

99 t been fully investigated in obesity-related metabolic disorders.

100 n protecting against HFD-induced obesity and metabolic disorders.

101 logical iron reduction on the development of metabolic disorders.

102 as a protective factor in obesity and other metabolic disorders.

103 tential therapeutic target for mTORC1-driven metabolic disorders.

104 esting potential target for the treatment of metabolic disorders.

105 eurodegenerative diseases are accompanied by metabolic disorders.

106 rimary cause of obesity and other eating and metabolic disorders.

107 n and oxidative stress in an animal model of metabolic disorders.

108 Its dysregulation causes diabetes and other metabolic disorders.

109 ight serve as a therapeutic target in common metabolic disorders.

110 ising target for therapeutic intervention in metabolic disorders.

111 ency hematologic disease (15.4%; p = 0.020), metabolic disorder (8.1%; p < 0.001), or solid malignanc

112 Clinical obesity is a complex metabolic disorder affecting one in three adults.

113 Maple syrup urine disease (MSUD) is a rare metabolic disorder, affecting the metabolism of branched

114 obesity (MO) programs offspring obesity and metabolic disorders, although the underlying mechanisms

115 ovide one of the first examples of ERT for a metabolic disorder and suggest that PEGylated CBS should

116 D and diabetes, potentiating both peripheral metabolic disorders and AD neuropathology.

117 reproduction, regenerative medicine, cancer, metabolic disorders and ageing.

118 Metabolic disorders and aging promote accumulation of am

119 ons have not been described in OTCD or other metabolic disorders and are not an associated finding in

120 ulin resistance are among the most prevalent metabolic disorders and are tightly associated with obes

121 road spectrum of diseases, including cancer, metabolic disorders and autoimmune diseases.

122 with a variety of human diseases, including metabolic disorders and cancer.

123 ory performance, neurodegenerative diseases, metabolic disorders and cancer.

124 ck, the disruption of which is implicated in metabolic disorders and cancer.

125 processing of IL1beta, contributing to many metabolic disorders and directing adipocytes to a more i

126 inhibition approaches for treating other PIP metabolic disorders and highlight the importance of modi

127 nding of the function of innate receptors in metabolic disorders and implicate TLR3 as a key control

128 ntially in those who are obese or have other metabolic disorders and in response to ingested nutrient

129 hepatic and systemic inflammation related to metabolic disorders and insulin resistance.

130 y liver disease is one of the most prevalent metabolic disorders and it tightly associates with obesi

131 this coupling is associated with a number of metabolic disorders and neurodegenerative diseases inclu

132 with a high impact on public health, such as metabolic disorders and neurodegenerative diseases.

133 romising drug targets for pharmacotherapy of metabolic disorders and obesity.

134 e-1 (SCD1) as a novel therapeutic target for metabolic disorders and other indications.

135 TX could represent a novel strategy to treat metabolic disorders and overcome current limitations of

136 y, potential functional interactions between metabolic disorders and psychiatric diseases are discuss

137 This knowledge has enabled the treatment of metabolic disorders and the development of antivirals an

138 we were able to show the true prevalence of metabolic disorders and therefore provided a valuable co

139 l environments predispose aging offspring to metabolic disorders and type 2 diabetes.

140 r (AHR) plays crucial roles in inflammation, metabolic disorder, and cancer.

141 hat is implicated in cardiovascular disease, metabolic disorder, and cancer.

142 uation of oxidative stress, ER stress, lipid metabolic disorder, and cell death signaling.

143 ion, autoimmune diseases, cardiovascular and metabolic disorders, and cancer reported in shift worker

144 ogies, including neurodegenerative diseases, metabolic disorders, and cancer.

145 oxicological functions in areas such as CNS, metabolic disorders, and cancers.

146 tant information about inherited or acquired metabolic disorders, and for monitoring the biochemical

147 sease, neurocognitive disease, osteoporosis, metabolic disorders, and physical frailty.

148 The finding that obesity and metabolic disorder are accompanied by chronic low-grade

149 Obesity-related metabolic disorders are characterized by mild chronic in

150 Metabolic disorders are common complications after ortho

151 Obesity and metabolic disorders are of great societal concern and ge

152 Inherited metabolic disorders are often characterized by the lack

153 Obesity and associated metabolic disorders are related to impairments of the in

154 played by this bacterium during obesity and metabolic disorders are unknown.

155 triggered significant inflammation and host metabolic disorders as a result of activation of bacteri

156 ently become a highly interesting target for metabolic disorders as well as for hepatitis C virus (HC

157 l polycystic ovary syndrome (PCOS), a common metabolic disorder associated with excess circulating an

158 Common metabolic disorders associated with active gluconeogenes

159 ch reduced with this technology, diminishing metabolic disorders associated with cooling and minimizi

160 ide a potential therapeutic means to control metabolic disorders associated with its dysregulated sec

161 re during pregnancy and childhood obesity or metabolic disorders at any age.

162 Given the rising incidence of metabolic disorders attributed to weight gain, changes i

163 This suggests the presence of an underlying metabolic disorder beyond fatty liver that may be causat

164 effects and mechanisms of PM2.5 exposure in metabolic disorders, but also revealed the pleotrophic a

165 ed in neurodegenerative, cardiovascular, and metabolic disorders, but the role of phospholipids, part

166 of CB1 ameliorates Diet-Induced Obesity and metabolic disorder by modulating macrophage inflammatory

167 nd shows that susceptibility of offspring to metabolic disorder can likely be attributed to epigeneti

168 remendous opportunities for the treatment of metabolic disorders, cancer, autoimmune diseases and etc

169 Gaucher's disease (GD), an inherited metabolic disorder caused by mutations in the glucocereb

170 biquitin ligase deficiency protects from the metabolic disorder caused by obesity.

171 Multisystem metabolic disorders caused by defects in oxidative phosp

172 n metabolism that can accumulate in numerous metabolic disorders, causing neurological dysfunction ra

173 irment in patients with diabetes mellitus, a metabolic disorder characterized by chronic hyperglycaem

174 Niemann-Pick Type C disease (NPC) is a rare metabolic disorder characterized by disruption of normal

175 Insulin resistance (IR) is a metabolic disorder characterized by impaired insulin sig

176 Pompe disease is a systemic metabolic disorder characterized by lack of acid-alpha g

177 We describe a metabolic disorder characterized by lipodystrophy, hepat

178 iderable value to the treatment algorithm of metabolic disorders characterized by dysregulated fatty

179 itive association between obesity-associated metabolic disorders (e.g., hyperlipidemia and diabetes)

180 Porphyrias are a group of eight metabolic disorders, each resulting from a mutation that

181 phalopathy (eg, caused by hepatic failure or metabolic disorders), encephalitis (caused by direct vir

182 tion, pneumonia, septicemia, nutritional and metabolic disorders, esophagitis, gastroenteritis, and d

183 gs should raise suspicion for this treatable metabolic disorder, especially when in the context of re

184 in the development of childhood obesity and metabolic disorders, especially when exposure occurs ear

185 Using the subnetwork of depression and metabolic disorders for functional analysis, the interac

186 at restore physiological feedback control in metabolic disorders foster advanced gene- and cell-based

187 The percentage of patients killed by metabolic disorder has been estimated to be 30% of the a

188 but the prevalence of obesity and associated metabolic disorders has risen dramatically.

189 Obesity and associated metabolic disorders have been implicated in liver carcin

190 pesticides (OCPs) have been linked to adult metabolic disorders; however, few studies have examined

191 rtant role in the development of obesity and metabolic disorders; however, it has not been fully unde

192 sing, metabolic switch implicated in various metabolic disorders; however, its role in inflammation i

193 ical molecular link between inflammation and metabolic disorders; however, the role of adipocyte IKKb

194 comutase 1 (PGM1) deficiency as an inherited metabolic disorder in humans.

195 Interestingly, the metabolic disorder in Miniature Poodles appears to share

196 olic fatty liver disease (NAFLD) is a common metabolic disorder in obese individuals.

197 g maternal HFD during lactation to persisted metabolic disorder in the offspring.

198 lic neural circuitry, leading to obesity and metabolic disorders in adulthood.

199 ptibility locus for dyslipidemia and related metabolic disorders in congenic and subcongenic rat stra

200 n but also promotes adiposity and associated metabolic disorders in fat-fed and aged mice.

201 of widespread occurrence of diet-associated metabolic disorders in global human populations.

202 may contribute to drug-induced steatosis and metabolic disorders in humans.

203 to prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals.

204 significantly contributes to skeletal muscle metabolic disorders in obesity.

205 Increasing evidence indicates that metabolic disorders in offspring can result from the fat

206 The association between metabolic disorders in offspring of obese mothers with d

207 ful for treating HFD-induced skeletal muscle metabolic disorders in such pathophysiological condition

208 from HFD males into normal zygotes generated metabolic disorders in the F1 offspring and altered gene

209 uced potential changes in pathophysiology of metabolic disorders in the liver.

210 Examination of metabolic disorders in treatment-refractory depression i

211 signalling is a pathogenic manifestation of metabolic disorders including obesity and diabetes.

212 turbation of circadian cycles contributes to metabolic disorders including type 2 diabetes.

213 risk in pregnancies complicated by maternal metabolic disorders, including diabetes and obesity.

214 stress, whereas superfluous lipolysis causes metabolic disorders, including dyslipidemia and hepatic

215 ila treatment reversed high-fat diet-induced metabolic disorders, including fat-mass gain, metabolic

216 omeostasis and its alterations contribute to metabolic disorders, including fatty liver and diabetes.

217 n obese mice and reversed the progression of metabolic disorders, including hepatic steatosis, glucos

218 Women with metabolic disorders, including obesity and diabetes, hav

219 s largely unknown despite important roles in metabolic disorders, including obesity and nonalcoholic

220 pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabet

221 Metabolic disorders, including obesity, diabetes, and ca

222 sue compartments is tightly linked to severe metabolic disorders, including obesity, metabolic syndro

223 nication between the brain and gut underlies metabolic disorders, including obesity.

224 ations in gut microbiota are associated with metabolic disorders, including obesity.

225 epatic PPARdelta-PC(18:0/18:1) signalling in metabolic disorders, including obesity.

226 ents a potential target for the treatment of metabolic disorders, including type 2 diabetes and obesi

227 p duration has been associated with risk for metabolic disorders, including weight gain, diabetes, ob

228 eficiency diseases or obesity and associated metabolic disorders, increased risk of cardiovascular di

229 chanism by which hypercholesterolemia or any metabolic disorder increases cancer risk remains unknown

230 training reduced the severity of most of the metabolic disorders induced by a fructose-rich diet and

231 aerobic, strength, and combined training on metabolic disorders induced by a fructose-rich diet.

232 se tissue endocannabinoid levels and prevent metabolic disorders induced by a later high-fat diet (HF

233 results suggest a novel mechanism by which a metabolic disorder induces epigenetic changes to reduce

234 the treatment of conditions associated with metabolic disorders, inhibit KSHV lytic replication.

235 pharmacological target for the treatment of metabolic disorders involving glucose metabolism.

236 Impaired AKT activation is a key factor in metabolic disorders involving insulin resistance, wherea

237 ension and related cardiovascular, renal and metabolic disorders is likely to become even more import

238 elevance to the long-term risk of developing metabolic disorders is unknown.

239 ormerly obese individuals are susceptible to metabolic disorders later in life, even after lifestyle

240 ascular system and metabolism, especially in metabolic disorders like diabetes.

241 ncludes the sections: Hypertension, Imaging, Metabolic Disorders & Lipids, Neurovascular & Neurodegen

242 ncludes the sections: Hypertension, Imaging, Metabolic Disorders & Lipids, Neurovascular & Neurodegen

243 Part Two includes the sections: Imaging, Metabolic Disorders & Lipids, Rhythm Disorders, Statisti

244 Part Two includes the sections: Imaging, Metabolic Disorders & Lipids, Rhythm Disorders, Statisti

245 urea cycle disorders (UCDs), rare inherited metabolic disorders manifested by hyperammonemia and neu

246 an Moco biosynthetic enzymes lead to a fatal metabolic disorder, Moco deficiency (MoCD).

247 ated with the mouse model for the congenital metabolic disorder mucopolysaccharidosis VII.

248 etroviral therapy frequently develop various metabolic disorders, neurocognitive abnormalities, and c

249 ommon pathogenic mechanisms shared by AD and metabolic disorders, notably obesity and T2D.

250 Dyslipidemia is a frequent component of the metabolic disorder of diabetic patients contributing to

251 e intermittent porphyria (AIP), an inherited metabolic disorder of heme biosynthesis in which an accu

252 uently, represent important drug targets for metabolic disorders of glucose homeostasis.

253 s a robust model for studying the effects of metabolic disorders on the central nervous system.

254 novel therapeutic targets for patients with metabolic disorder or T2D who suffer from anxiety and de

255 ue for noninvasive, early-stage diagnosis of metabolic disorders or diseases.

256 ities commonly associated with the inherited metabolic disorder, phenylketonuria.

257 ted with specific feeding diets and possible metabolic disorders related to diet.

258 nisms underlying the role of this protein in metabolic disorders remain unclear.

259 relationship between the bacteria and these metabolic disorders remains a matter of debate.

260 of adipocyte IKKbeta in obesity and related metabolic disorders remains elusive.

261 vity leads to debilitating neuroendocrine or metabolic disorders such as Cushing's syndrome (CS).

262 he association between sleep deprivation and metabolic disorders such as diabetes and obesity require

263 bolic processes, and its disruption leads to metabolic disorders such as diabetes and obesity.

264 represent a candidate therapeutic target for metabolic disorders such as dyslipidemia.

265 zing radiation increases the risk of chronic metabolic disorders such as insulin resistance and type

266 ntributes to the dyslipidemia seen in common metabolic disorders such as insulin-resistant states and

267 Moreover, we also discuss advances on how metabolic disorders such as metabolic syndrome and diabe

268 in epigenetic regulation are associated with metabolic disorders such as obesity and diabetes that ar

269 energy balance are urgently needed to combat metabolic disorders such as obesity and diabetes.

270 nificant evidence linking gut microbiota and metabolic disorders such as obesity and diabetes.

271 organ systems and offers protection against metabolic disorders such as obesity and diabetes.

272 ne with age and is implicated in age-related metabolic disorders such as obesity and type 2 diabetes

273 between intestinal microbial composition and metabolic disorders such as obesity and type 2 diabetes.

274 ute an appealing target for the treatment of metabolic disorders such as obesity, diabetes and hyperl

275 ection between an altered gut microbiota and metabolic disorders such as obesity, diabetes, and cardi

276 rcadian clock disruption are associated with metabolic disorders such as obesity, insulin resistance,

277 ontribute to neuronal function as well as to metabolic disorders such as type 2 diabetes mellitus, ob

278 tis has been implicated as a risk factor for metabolic disorders such as type 2 diabetes, atheroscler

279 R stress has been implicated in a variety of metabolic disorders, such as obesity and type 2 diabetes

280 cerbate the development and/or prevalence of metabolic disorders, such as obesity, is currently of gr

281 considered promising therapeutics for common metabolic disorders, such as obesity, liver steatosis, a

282 ism and the pathophysiology of lipid-related metabolic disorders, such as obesity.

283 uman adipose tissue (hAT) is a key player in metabolic disorders, such as Type 2 Diabetes Mellitus (T

284 AIT cell abnormalities in patients harboring metabolic disorders, suggesting their potential role in

285 HCS cause holocarboxylase deficiency, a rare metabolic disorder that can be life-threatening if left

286 liver disease (NAFLD), a widespread hepatic metabolic disorder that is believed to be a risk factor

287 r, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF

288 ced gene expression patterns associated with metabolic disorders that were identified in blastocysts

289 sorders, such as cardiovascular diseases and metabolic disorders, that influence significantly (and i

290 in the development of obesity and associated metabolic disorders, the incidence of metabolic syndrome

291 ed lipolysis is linked to the development of metabolic disorders, the inhibition of ATGL by G0S2-deri

292 are linked to diseases spanning genetic and metabolic disorders to cancer and neurodegeneration.

293 Defects in P5CDH activity lead to the metabolic disorder type II hyperprolinemia, P5CDH is ess

294 een shown to exhibit increased prevalence of metabolic disorders (type-2 diabetes, cardiovascular dis

295 le of LMP7 in the development of obesity and metabolic disorders using LMP7-deficient mice.

296 N-CDs) electrode for the screening of purine metabolic disorder was described in this paper.

297 ckout model demonstrates multiple immune and metabolic disorders, we investigated the role of each re

298 sed dysregulated splicing events and hepatic metabolic disorders, which trigger endoplasmic reticulum

299 iencies (MADDs) are a heterogeneous group of metabolic disorders with combined respiratory-chain defi

300 er, the role of adipocytes in linking energy metabolic disorders with insulin regulation is unknown i